The outcomes in the relative effectiveness associated with remedy for post-stroke depression with fluvoxamine monotherapy while the mixture of fluvoxamine and cytoflavin verified the great effectiveness associated with combo treatment, that ought to cell biology be taken into consideration whenever building brand-new therapy regimens for post-stroke depression, and the importance of recommending antidepressants and anti-oxidant drugs is determined predicated on an individual evaluation associated with the extent of depressive condition and parameters of oxidative tension endogenous anti-oxidant activities in every individual patient with ischemic stroke. The analysis included 93 customers (55 males and 38 women) 27 with focal epilepsy (FE) and 66 with idiopathic generalized epilepsy (IGE). Patients with idiopathic and age-dependent FE are not included in the research. At each visit, video-EEG tracking using the evaluation of focal, diffuse and generalized epileptiform task during wakefulness before sleep, during sleep, after sleep and during partial awakenings with quantitative EAI assessment at baseline, after 1, 3, 6 and one year of therapy was done. Therapeutic medicine tracking had been performed during dosage titration 30 days after the beginning of therapy or perhaps in situation of therapy modification. Treatment efficacy was considered based on the absence of seizures, decrease of seizure episodes by more than 50per cent (responders) and <50% (inadequate efficacy). Adverseakenings in the first months of therapy (1-3 months). EAI objectively reflects the characteristics of VA treatment efficacy.VA stays among the medications of choice in IGE and FE. EAI can become an additional goal test in situations of tough differential analysis in IGE and FE, using total EAI, EAI before sleep, during sleep, during partial awakenings in the first months of treatment (1-3 months). EAI objectively reflects the dynamics of VA treatment efficacy. To designate the objectives for health and psychotherapeutic effects in patients with comorbid recurrent affective and anxiety attacks on the basis of the research of intellectual functions. a battery pack of pathopsychological tests («Schulte Table», «Corrective Test», «Ten Words test», «Cube Drawing Technique», Binet and Berstein Tests) has been used to evaluate the neuro-cognitive status of 60 clients with symptoms of recurrent affective (depressive) and anxiety attacks. Relating to ICD-10, 27 patients being identified with recurrent affective condition with a mild or moderate depressive episode (RAD, F33.0, F33.1) in conjunction with panic attacks (PD, F41.0). The control group included 33 customers with recurrent affective disorder with a mild to moderate depressive episode (RAD, F33.0, F33.1) without panic disorder. All of the patients showed the alterations in the intellectual world. In customers with recurrent affective condition in conjunction with panic disorder, cognitive impairment had been much more pronounced than that in customers from the control group. Intellectual features in customers with recurrent affective and comorbid panic disorder were distinguished by their peculiarity, which manifested itself in «left hemisphere» disorders in the shape of paroxysmal mental disorders using the predominance of fear and anxiety affect, work dysfunction in many different neuropsychological aspects successiveness, spatial, inertness-mobility, for which mediobasal and subcortical areas of the mind are responsible. The goals for medical and psychotherapeutic results in patients with comorbid panic and recurrent depressive condition are attention, auditory and verbal memory, thinking components (rational and spatial). It really is reasonable to use neuropsychological correction of intellectual impairment in this band of clients.Its reasonable to use neuropsychological modification of cognitive disability in this group of clients. Patients, elderly from 19 to 44 years, had been distributed into three teams, 30 clients in each clients after several (initially) epileptic seizures, patients when you look at the medical remission that includes lasted at least one year, and customers with treatment-resistant epileptic seizures. The control team included 20 healthier men and women. Variables for the pro-oxidant standing (TBA-reactive items) plus the antioxidant defense (total superoxide-scavenging activity, catalase, complete antioxidant activity, and paid off thiols (SH teams)) had been calculated when you look at the bloodstream plasma. No significant differences in the levels of TBA-reactive products had been identified in clients with epilepsy compared with healthy settings while levels of reduced SH groups, total superoxide-scavenging task, catalase activity and also the complete antioxidant activity were substantially reduced in clients. In addition, a few of the variables exhibited considerable differences when considering different groups of patients. In patients with epilepsy, the alterations in the free-radical procedures are noticed currently after the first seizures and persist in the treatment-resistant epilepsy as well as in medical remission. Considering that the variables of this task of the anti-oxidant security tend to be significantly different in numerous sets of patients, you can assume that varying elements of this oxidative stress are present following the first epileptic seizures and in different classes associated with the disease.